Scarica l'app Stockscreener
0.00
100.00%
-93.80
Dopo l'orario di chiusura:
2.65
2.65
+
Aerovate Therapeutics Inc Borsa (AVTE) Ultime notizie
Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Up 2.3% – Still a Buy? - Defense World
Aerovate Therapeutics (AVTE) Projected to Post Earnings on Monday - Defense World
Rhumbline Advisers Acquires 9,154 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Deep Track Capital, LP Acquires New Holdings in Aerovate Therapeutics Inc - GuruFocus
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
Aerovate Therapeutics (NASDAQ:JBIO) Upgraded to Buy at Guggenheim - Defense World
Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14 - MarketScreener
Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation - Investing.com Canada
Aerovate Therapeutics (NASDAQ:JBIO) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Millennium Management LLC Cuts Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
FMR LLC's Strategic Acquisition of Aerovate Therapeutics Inc Shares - GuruFocus
19,564 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Purchased by Squarepoint Ops LLC - Defense World
Bank of America Corp DE Has $612,000 Stock Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Two Sigma Investments LP Cuts Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Two Sigma Advisers LP Grows Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Northern Trust Corp Purchases 6,296 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
BNP Paribas Financial Markets Makes New Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Aerovate Therapeutics (AVTE) to Release Earnings on Monday - Defense World
Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
Aerovate Therapeutics Declares Special Cash Dividend In Connection With The Proposed Merger With Jade Biosciences - marketscreener.com
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
Aerovate Therapeutics Announces Range Of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Aerovate Therapeutics Inc (AVTE)’s financial ratios: A comprehensive overview - DWinneX
JBIO Stock Price and Chart — NASDAQ:JBIO - TradingView
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE St - GuruFocus
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE Stock News - GuruFocus
Jade Biosciences merges with Aerovate Therapeutics07:00:02 29 Apr 2025RTW News article - London Stock Exchange
Traders Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Jade Biosciences closes merger with Aerovate Therapeutics - Coast Reporter
Aerovate Therapeutics Inc (AVTE) gets rating Downgrade from Wells Fargo - knoxdaily.com
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million - Benzinga
Russell Investments Group Ltd. Boosts Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics Inc (AVTE) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Aerovate Therapeutics (AVTE) Soars 721.88% on Merger, Dividend News - AInvest
AVTE’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) - Barchart.com
AVTE Shares Experience Decline in Value - knoxdaily.com
Aerovate Therapeutics (AVTE) Declares Special Dividend Amid Merg - GuruFocus
Aerovate approves reverse split ahead of Jade merger By Investing.com - Investing.com South Africa
Aerovate Therapeutics and Jade Biosciences Merger Approved - citybiz
Aerovate Stockholders Approve Merger Proposal With Jade Biosciences - Nasdaq
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate (AVTE) Stockholders Approve Merger with Jade Biosciences | AVTE Stock News - GuruFocus
Aerovate Therapeutics Approves Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com
Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals - PR Newswire
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):